AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29533038 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative imaging outcomes
Number of subjects: 76
Study 29533038 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative Harris score comparison
Number of subjects: 76
Study 26254196 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaria palmata-enriched bread (5 g/day)
Number of subjects: 0
Study 26254196 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 24956002 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin cancer videos
Number of subjects: 63
Study 23276777 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership delivery system
Number of subjects: 11960
Study 23276777 — intervention group
Group type: COMPARATOR
Intervention: Usual-programming conditions
Number of subjects: 11960
Study 19502018 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholemeal wheat foods
Number of subjects: 15
Study 19502018 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat foods
Number of subjects: 15
Study 17869018 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine during radiotherapy
Number of subjects: 170
Study 17869018 — intervention group
Group type: COMPARATOR
Intervention: Placebo during radiotherapy
Number of subjects: 170
Study 16803603 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (omeprazole, amoxicillin, and clarithromycin)
Number of subjects: 693
Study 16803603 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo/omeprazole)
Number of subjects: 693
Study 14709953 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 to 400 mg/d for 4 weeks)
Number of subjects: 35
Study 11281824 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprotective agents (specific agents not mentioned)
Number of subjects: 0
Study 11281824 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 9630856 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine Needle Biopsy (FNB)
Number of subjects: 129
Study 8142099 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine with epinephrine 3.75 micrograms/ml (Group A)
Number of subjects: 48
Study 8142099 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine 5 micrograms/ml (Group B)
Number of subjects: 48
Study 8142099 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain 0.5% bupivacaine (Group C)
Number of subjects: 48
Study 8142099 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (Group D)
Number of subjects: 48
Study 3147196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate inhaled at maximum flow rate (V1)
Number of subjects: 7
Study 3147196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate inhaled at 100 l.min‐1 (V2)
Number of subjects: 7
Study 3147196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate inhaled at 50 l.min‐1 (V3)
Number of subjects: 7
Study 3147196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29951734 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 µg
Number of subjects: 2246
Study 29951734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2246
Study 27997652 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical activity participation (light aerobic exercise, sport-specific exercise, noncontact drills, full-contact practice, full competition)
Number of subjects: 3063
Study 27997652 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical activity participation
Number of subjects: 3063
Study 27997652 — intervention group
Group type: COMPARATOR
Intervention: Light aerobic activity
Number of subjects: 3063
Study 27997652 — intervention group
Group type: COMPARATOR
Intervention: Moderate activity
Number of subjects: 3063
Study 27997652 — intervention group
Group type: COMPARATOR
Intervention: Full-contact activity
Number of subjects: 3063
Study 27997652 — intervention group
Group type: COMPARATOR
Intervention: No physical activity
Number of subjects: 3063
Study 25717040 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders of God
Number of subjects: 0
Study 25717040 — intervention group
Group type: COMPARATOR
Intervention: No reminders of God
Number of subjects: 0
Study 23992191 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (doses not specified)
Number of subjects: 264
Study 20406224 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 160
Study 20406224 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 100 mg
Number of subjects: 160
Study 20406224 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 160
Study 20406224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 18336487 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension-extension position
Number of subjects: 20
Study 18336487 — intervention group
Group type: COMPARATOR
Intervention: Sniffing position
Number of subjects: 20
Study 16271816 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct condition
Number of subjects: 6
Study 16271816 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbed condition
Number of subjects: 6
Study 16271816 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (5)
Number of subjects: 6
Study 16271816 — intervention group
Group type: COMPARATOR
Intervention: Perturbation of object position and distance
Number of subjects: 6
Study 12660685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate in addition to aspirin and ticlopidine
Number of subjects: 79
Study 12660685 — intervention group
Group type: COMPARATOR
Intervention: No sarpogrelate (Control group)
Number of subjects: 79
Study 11082213 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 2 (30% fat intake)
Number of subjects: 531
Study 11082213 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 1 (30% fat intake)
Number of subjects: 531
Study 11082213 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets 3 and 4 (22% and 18% fat intake)
Number of subjects: 531
Study 11082213 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP Step II diet
Number of subjects: 531
Study 9360032 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) with the Odstock Dropped Foot Stimulator (ODFS) and physiotherapy
Number of subjects: 32
Study 9360032 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 32
Study 8248747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX)
Number of subjects: 39
Study 8248747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTR)
Number of subjects: 39
Study 8248747 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastine (I/C)
Number of subjects: 39
Study 2431344 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 3
Study 2431344 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 3
Study 2431344 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 3
Study 31385378 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo condition (one-third of pain stimuli conditioned)
Number of subjects: 53
Study 31385378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction condition (after two consecutive nights at work)
Number of subjects: 53
Study 31385378 — intervention group
Group type: COMPARATOR
Intervention: Control condition (habitual sleep)
Number of subjects: 53
Study 30284585 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1 μg/kg prior to induction, 0.05-0.5 μg/kg/minute during maintenance)
Number of subjects: 30
Study 30284585 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg prior to induction, 0.2-0.7 μg/kg/hour during maintenance)
Number of subjects: 30
Study 30284585 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 27632145 — intervention group
Group type: EXPERIMENTAL
Intervention: Health system navigator intervention (in-person interview, phone calls, text messages over 4 months)
Number of subjects: 4903
Study 27632145 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4903
Study 27632145 — intervention group
Group type: EXPERIMENTAL
Intervention: Health system navigator intervention
Number of subjects: 4903
Study 27632145 — intervention group
Group type: EXPERIMENTAL
Intervention: Health system navigator intervention (≥5 calls)
Number of subjects: 4903
Study 24525641 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 39
Study 24525641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 22024470 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD-delivered, home-based, physical activity intervention
Number of subjects: 300
Study 22024470 — intervention group
Group type: COMPARATOR
Intervention: Healthy Aging attention control condition
Number of subjects: 300
Study 20121708 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier continuous Kangaroo Mother Care (KMC)
Number of subjects: 73
Study 20121708 — intervention group
Group type: COMPARATOR
Intervention: Later continuous Kangaroo Mother Care (KMC)
Number of subjects: 73
Study 18547903 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily regimen of efavirenz, extended-release stavudine, and lamivudine (QD arm)
Number of subjects: 320
Study 18547903 — intervention group
Group type: COMPARATOR
Intervention: Existing therapy (BID+ arm)
Number of subjects: 320
Study 15823287 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated backscatter (IB) ultrasound in patients with systemic sclerosis (SSc)
Number of subjects: 62
Study 15823287 — intervention group
Group type: COMPARATOR
Intervention: Integrated backscatter (IB) ultrasound in control subjects
Number of subjects: 62
Study 15823287 — intervention group
Group type: COMPARATOR
Intervention: Correlation of IB values with age in control subjects
Number of subjects: 62
Study 15823287 — intervention group
Group type: COMPARATOR
Intervention: Correlation of IB values with intima‐media thickness in control subjects
Number of subjects: 62
Study 15823287 — intervention group
Group type: COMPARATOR
Intervention: Correlation of IB values with stiffness beta in control subjects
Number of subjects: 62
Study 15823287 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IB values with elastic fragmentation index
Number of subjects: 62
Study 15823287 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IB values with collagen fiber index
Number of subjects: 62
Study 12849809 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of 300 IU rFSH
Number of subjects: 19
Study 12849809 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular administration of 300 IU rFSH
Number of subjects: 19
Study 12849809 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of rFSH
Number of subjects: 19
Study 12849809 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular administration of rFSH
Number of subjects: 19
Study 10543671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-debt condition (4 hours of sleep per night for 6 nights)
Number of subjects: 11
Study 10543671 — intervention group
Group type: COMPARATOR
Intervention: Fully rested condition (12 hours of sleep per night for 6 nights)
Number of subjects: 11
Study 9032569 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 82
Study 9032569 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens with cyclical progestogen
Number of subjects: 82
Study 9032569 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol alone
Number of subjects: 82
Study 9032569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy other than calcium)
Number of subjects: 82
Study 9032569 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of treatment groups
Number of subjects: 82
Study 9032569 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone or conjugated equine estrogens
Number of subjects: 82
Study 9032569 — intervention group
Group type: EXPERIMENTAL
Intervention: All therapies
Number of subjects: 82
Study 2007040 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (4.2 +/- 1.4 mg loading dose; 8.6 +/- 5.4 mg/h maintenance infusion)
Number of subjects: 68
Study 2007040 — intervention group
Group type: COMPARATOR
Intervention: Propofol (69 +/- 23 mg loading dose; 265 +/- 185 mg/h maintenance infusion)
Number of subjects: 68
Study 2007040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Midazolam and Propofol
Number of subjects: 68
Study 6812849 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 1200 mg flumequine orally
Number of subjects: 239
Study 6812849 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose regimen of 1200 and 800 mg flumequine
Number of subjects: 239
Study 6812849 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of 1200, 800, and 800 mg flumequine (six hours apart)
Number of subjects: 239
Study 6812849 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients harbouring beta-lactamase-producing gonococci treated with flumequine
Number of subjects: 239
Study 6812849 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects noted by patients
Number of subjects: 239
Study 30874754 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (n=79)
Number of subjects: 155
Study 30874754 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic medication (n=76)
Number of subjects: 155
Study 28541187 — intervention group
Group type: EXPERIMENTAL
Intervention: cBCI-assisted group decisions
Number of subjects: 10
Study 28541187 — intervention group
Group type: COMPARATOR
Intervention: Majority-based group decisions
Number of subjects: 10
Study 26515428 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG optimization
Number of subjects: 19
Study 26515428 — intervention group
Group type: COMPARATOR
Intervention: ECHO optimization
Number of subjects: 19
Study 24601726 — intervention group
Group type: EXPERIMENTAL
Intervention: High fructose (HF; 80 g/d)
Number of subjects: 34
Study 24601726 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium fructose (MF; 40 g/d)
Number of subjects: 34
Study 24601726 — intervention group
Group type: EXPERIMENTAL
Intervention: High sucrose (HS; 80 g/d)
Number of subjects: 34
Study 24601726 — intervention group
Group type: EXPERIMENTAL
Intervention: High glucose (HG; 80 g/d)
Number of subjects: 34
Study 21948223 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk factors for prolonged diarrhea
Number of subjects: 0
Study 21948223 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea >7 days
Number of subjects: 0
Study 21948223 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe dehydration after hospitalization
Number of subjects: 0
Study 19262203 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information provided before cardiac enzyme tests (CET)
Number of subjects: 523
Study 19262203 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information provided via leaflet
Number of subjects: 523
Study 19262203 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and providing information with a leaflet
Number of subjects: 523
Study 19262203 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing at least one procedure (monitoring, ECG, chest radiograph)
Number of subjects: 523
Study 17461312 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition group (oral supplementation for five days before and five days after surgery with 900 mL/day of a formula enriched with arginine, gamma‐3‐fatty acid and RNA + liquid diet ad libitum on one and two postoperative day and then solid food)
Number of subjects: 100
Study 17461312 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (no artificial nutrition before and after surgery, on one and two postoperative day intravenous solution of 5% glucose and electrolytes and then normal diet)
Number of subjects: 100
Study 15214299 — intervention group
Group type: EXPERIMENTAL
Intervention: 15,000 IU/week vitamin D
Number of subjects: 52
Study 15214299 — intervention group
Group type: COMPARATOR
Intervention: Calcium 0.5 g/d and placebo
Number of subjects: 52
Study 12585818 — intervention group
Group type: EXPERIMENTAL
Intervention: Asperger Syndrome individuals
Number of subjects: 28
Study 12585818 — intervention group
Group type: COMPARATOR
Intervention: Healthy age and gender matched controls
Number of subjects: 28
Study 11147152 — intervention group
Group type: EXPERIMENTAL
Intervention: Open kinetic chain (OKC) exercise
Number of subjects: 36
Study 11147152 — intervention group
Group type: COMPARATOR
Intervention: Closed kinetic chain (CKC) exercise
Number of subjects: 36
Study 8822046 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg t.i.d. for one week)
Number of subjects: 11
Study 1456855 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (9.98 mmol [400 mg] of elemental calcium) three times daily with meals for 6 weeks
Number of subjects: 56
Study 1456855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 6390462 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg nicotinic acid alone per day for 30 days
Number of subjects: 12
Study 6390462 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg nicotinic acid plus 60,000 U retinol and 140 mg tocopherols per day for 30 days
Number of subjects: 12
Study 31171092 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 468
Study 31171092 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 468
Study 31171092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 29696507 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable artesunate (Inj AS)
Number of subjects: 1103
Study 26967214 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg ABT-126
Number of subjects: 434
Study 26967214 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg ABT-126
Number of subjects: 434
Study 26967214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study 26967214 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-126 (both doses)
Number of subjects: 434
Study 23937282 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 228
Study 23937282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 228
Study 23937282 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline or Nortriptyline (as monotherapy or adjuvant therapy)
Number of subjects: 228
Study 21680806 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational community intervention taught by promotoras de salud
Number of subjects: 328
Study 21680806 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 328
Study 20465752 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined methodology using the QCL Kinetic Chromogenic Assay to detect endotoxin activity
Number of subjects: 211
Study 19046724 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg/day
Number of subjects: 68
Study 19046724 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/day
Number of subjects: 68
Study 15888513 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic exposed (< 12 weeks)
Number of subjects: 535
Study 15888513 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed
Number of subjects: 535
Study 12766094 — intervention group
Group type: EXPERIMENTAL
Intervention: nateglinide (120 mg a.c.) added to rosiglitazone monotherapy (8 mg q.d.)
Number of subjects: 402
Study 12766094 — intervention group
Group type: COMPARATOR
Intervention: placebo added to rosiglitazone monotherapy
Number of subjects: 402
Study 10570675 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help group
Number of subjects: 330
Study 10570675 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-instruction group
Number of subjects: 330
Study 8918486 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin 100 mg/m2 at 2-week intervals for three cycles with pelvic radiation
Number of subjects: 99
Study 8918486 — intervention group
Group type: COMPARATOR
Intervention: Radiation without chemotherapy (Control)
Number of subjects: 99
Study 1917089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubliseal (glass ionomer luting cement)
Number of subjects: 90
Study 1917089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Cem (glass ionomer luting cement)
Number of subjects: 90
Study 1917089 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia Ex (chemically active composite resin)
Number of subjects: 90
Study 1917089 — intervention group
Group type: COMPARATOR
Intervention: Lateral condensation of gutta‐percha with Tubliseal
Number of subjects: 90
Study 1917089 — intervention group
Group type: COMPARATOR
Intervention: Lateral condensation of gutta‐percha with Ketac Cem
Number of subjects: 90
Study 1917089 — intervention group
Group type: COMPARATOR
Intervention: Lateral condensation of gutta‐percha with Panavia Ex
Number of subjects: 90
Study 31937296 — intervention group
Group type: EXPERIMENTAL
Intervention: Goodform intervention (teacher-delivered, four sessions)
Number of subjects: 0
Study 29097225 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose miconazole suppository
Number of subjects: 45
Study 29097225 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose miconazole suppository
Number of subjects: 45
Study 29097225 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose miconazole cream
Number of subjects: 45
Study 29097225 — intervention group
Group type: COMPARATOR
Intervention: CVR only
Number of subjects: 45
Study 27935973 — intervention group
Group type: EXPERIMENTAL
Intervention: InSight‐Hemianopia Compensatory Scanning Training (IH‐CST)
Number of subjects: 0
Study 24804220 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric resistance training
Number of subjects: 77
Study 24804220 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional resistance training
Number of subjects: 77
Study 24804220 — intervention group
Group type: EXPERIMENTAL
Intervention: High IMAT group
Number of subjects: 77
Study 24804220 — intervention group
Group type: EXPERIMENTAL
Intervention: Low IMAT group
Number of subjects: 77
Study 22930766 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia restorations
Number of subjects: 37